UnknownNot Applicable

Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts

Egypt58 participantsStarted 2022-06-01

Plain-language summary

This study aims to investigate the relationship between HPV genotypes and treatment outcomes of intralesional immunotherapy of anogenital warts with the quadrivalent vaccine (Gardasil).

Who can participate

Age range20 Years – 60 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Patients with clinically diagnosed multiple anogenital warts who had not received treatment in the last 2 months before the study Exclusion Criteria: * Patient refusal, pregnancy, lactation, age less than 10 years, and immunosuppressive conditions

What they're measuring

improvement of lesion

Timeframe: 6 month

Trial details

NCT IDNCT05761002

SponsorZagazig University

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2023-06-01

View on ClinicalTrials.gov More Human Papilloma Virus trials